Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Assessing the heterogeneity of KRAS-mutant pancreatic adenocarcinomas

Bach Ardalan, MD, University of Miami, Coral Gables, FL, discusses the differences between the different the three KRAS G12D, G12V, and G12R mutations in pancreatic ductal adenocarcinoma (PDAC). In an analysis of PDAC samples, the G12D mutation was associated with lower survival. Dr Ardalan additionally highlights molecular differences between the three KRAS mutations. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.